한글목차

개요

헤파린 시장은 예측 기간 중 연평균 복합 성장률(CAGR)은 7.22%를 나타낼 전망이며, 2023년부터 2027년에 걸쳐 33억 4,000만 달러 확대될 것으로 예측됩니다.

헤파린 시장에 대한 전체적인 분석, 시장 규모와 예측, 동향, 성장 촉진요인, 과제, 약 25개 벤더를 대상으로 한 벤더 분석 등의 정보를 게재했습니다.

현재 세계 시장 시나리오, 최신 동향과 촉진요인, 시장 환경 전체에 관한 최신 분석을 제공합니다. 응고 장애 유병률 증가, 만성질환 유병률 증가, 헤파린을 생산하기 위한 대체 소스 재도입에 의해 시장 성장이 촉진되고 있습니다.

본 조사에서는 헤파린 연구개발 활동 증가와 새로운 치료 용도를 향후 몇 년간 헤파린 시장 성장을 촉진하는 주요 이유 중 하나로 특정하고 있습니다. 바이오시밀러 저분자 헤파린의 등장, 수술 후 헤파린을 제거하는 약제 개발은 시장의 높은 수요로 연결될 전망입니다.

목차

제1장 주요 요약

• 시장 개요

제2장 시장 구도

• 시장 생태계

제3장 시장 규모

• 시장의 정의
• 시장 부문 분석
• 시장 규모(2023년)
• 시장 전망(2023-2028년)

제4장 시장 규모 실적

• 세계의 헤파린 시장(2018-2022년)
• 제품별 부문 분석(2018-2022년)
• 투여 경로별 부문 분석(2018-2022년)
• 지역별 부문 분석(2018-2022년)
• 국가별 부문 분석(2018-2022년)

제5장 Five Forces 분석

• Five Forces 요약
• 바이어의 교섭력
• 공급 기업의 교섭력
• 신규 진출업체의 위협
• 대체품의 위협
• 경쟁 위협
• 시장 현황

제6장 시장 세분화 : 제품별

• 시장 부문
• 비교 : 제품별
• 저분자량 헤파린 : 시장 규모와 예측(2023-2028년)
• 기타 : 시장 규모와 예측(2023-2028년)
• 시장 기회 : 제품별

제7장 시장 세분화 : 투여 경로별

• 시장 부문
• 비교 : 투여 경로별
• 피하 주사 : 시장 규모와 예측(2023-2028년)
• 점적 정맥주사 : 시장 규모와 예측(2023-2028년)
• 시장 기회 : 투여 경로별

제8장 고객 상황

• 고객 상황 개요

제9장 지역별 상황

• 지역별 세분화
• 지역별 비교
• 유럽 : 시장 규모와 예측(2023-2028년)
• 북미 : 시장 규모와 예측(2023-2028년)
• 아시아 : 시장 규모와 예측(2023-2028년)
• 세계 기타 지역 : 시장 규모와 예측(2023-2028년)
• 미국 : 시장 규모와 예측(2023-2028년)
• 영국 : 시장 규모와 예측(2023-2028년)
• 독일 : 시장 규모와 예측(2023-2028년)
• 중국 : 시장 규모와 예측(2023-2028년)
• 프랑스 : 시장 규모와 예측(2023-2028년)
• 시장 기회 : 지역 상황별

제10장 성장 촉진요인, 과제 및 동향

• 시장 성장 촉진요인
• 시장이 해결해야 할 과제
• 성장 촉진요인과 과제의 영향
• 시장 동향

제11장 벤더 구도

• 개요
• 벤더 구도
• 혼란 상황
• 업계 리스크

제12장 벤더 분석

• 대상 벤더
• 벤더의 시장 포지셔닝
• Aspen Pharmacare Holdings Ltd
• B.Braun SE
• Baxter International Inc.
• Eisai Co. Ltd.
• Fresenius SE and Co. KGaA
• Hikma Pharmaceuticals Plc
• Laboratorios Farmaceuticos ROVI S A
• Nanjing Kingfriend Biochemical
• Nichi Iko Pharmaceutical Co. Ltd.
• Novartis AG
• Pfizer Inc.
• Sanofi SA
• Shenzhen Techdow Pharmaceutical
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

제13장 부록

영문목차

Abstract

Technavio has been monitoring the heparin market and is poised to grow by $3.34bn from 2023-2027, accelerating at a CAGR of 7.22% during the forecast period. Our report on the heparin market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of coagulation disorders, the increasing prevalence of chronic conditions, and the reintroduction of alternative sources to produce heparin.

Technavio's heparin market is segmented as below:

By Product

• Low-molecular-weight heparin
• Others

By Route of Administration

• Subcutaneous injection
• Intravenous/infusion

By Geographical Landscape

• Europe
• North America
• Asia
• Rest of World (ROW)

This study identifies the increasing R&D activities and new therapeutic applications of heparin as one of the prime reasons driving the heparin market growth during the next few years. Also, the advent of biosimilar low-molecular-weight heparin and the development of drugs to remove heparin after surgery will lead to sizable demand in the market.

• Heparin market sizing
• Heparin market forecast
• Heparin market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading heparin market vendors that include Aspen Pharmacare Holdings, B. Braun SE, Baxter International Inc., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Fresenius SE and Co. KGaA, Hebei Changshan Biochemical, Hikma Pharmaceuticals Plc, Laboratorios Farmaceuticos Rovi, LEO Pharma AS, Nanjing Kingfriend Biochemical, Nichi Iko Pharmaceutical Co. Ltd., Novartis AG, Opocrin SpA, Pfizer Inc., Sanofi SA, Shanghai Fosun Pharmaceutical Group Co. Ltd., Shenzhen Techdow Pharmaceutical, Teva Pharmaceutical Industries Ltd., and Viatris Inc. Also, the heparin market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Route of Administration
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028
• Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
• Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

• 4.1 Global heparin market 2018 - 2022
• Exhibit 18: Historic Market Size - Data Table on global heparin market 2018 - 2022 ($ billion)
• 4.2 Product Segment Analysis 2018 - 2022
• Exhibit 19: Historic Market Size - Product Segment 2018 - 2022 ($ billion)
• 4.3 Route Of Administration Segment Analysis 2018 - 2022
• Exhibit 20: Historic Market Size - Route Of Administration Segment 2018 - 2022 ($ billion)
• 4.4 Geography Segment Analysis 2018 - 2022
• Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
• 4.5 Country Segment Analysis 2018 - 2022
• Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Product

• 6.1 Market segments
• Exhibit 30: Chart on Product - Market share 2023-2028 (%)
• Exhibit 31: Data Table on Product - Market share 2023-2028 (%)
• 6.2 Comparison by Product
• Exhibit 32: Chart on Comparison by Product
• Exhibit 33: Data Table on Comparison by Product
• 6.3 Low-molecular-weight heparin - Market size and forecast 2023-2028
• Exhibit 34: Chart on Low-molecular-weight heparin - Market size and forecast 2023-2028 ($ billion)
• Exhibit 35: Data Table on Low-molecular-weight heparin - Market size and forecast 2023-2028 ($ billion)
• Exhibit 36: Chart on Low-molecular-weight heparin - Year-over-year growth 2023-2028 (%)
• Exhibit 37: Data Table on Low-molecular-weight heparin - Year-over-year growth 2023-2028 (%)
• 6.4 Others - Market size and forecast 2023-2028
• Exhibit 38: Chart on Others - Market size and forecast 2023-2028 ($ billion)
• Exhibit 39: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
• Exhibit 40: Chart on Others - Year-over-year growth 2023-2028 (%)
• Exhibit 41: Data Table on Others - Year-over-year growth 2023-2028 (%)
• 6.5 Market opportunity by Product
• Exhibit 42: Market opportunity by Product ($ billion)
• Exhibit 43: Data Table on Market opportunity by Product ($ billion)

7 Market Segmentation by Route of Administration

• 7.1 Market segments
• Exhibit 44: Chart on Route of Administration - Market share 2023-2028 (%)
• Exhibit 45: Data Table on Route of Administration - Market share 2023-2028 (%)
• 7.2 Comparison by Route of Administration
• Exhibit 46: Chart on Comparison by Route of Administration
• Exhibit 47: Data Table on Comparison by Route of Administration
• 7.3 Subcutaneous injection - Market size and forecast 2023-2028
• Exhibit 48: Chart on Subcutaneous injection - Market size and forecast 2023-2028 ($ billion)
• Exhibit 49: Data Table on Subcutaneous injection - Market size and forecast 2023-2028 ($ billion)
• Exhibit 50: Chart on Subcutaneous injection - Year-over-year growth 2023-2028 (%)
• Exhibit 51: Data Table on Subcutaneous injection - Year-over-year growth 2023-2028 (%)
• 7.4 Intravenous infusion - Market size and forecast 2023-2028
• Exhibit 52: Chart on Intravenous infusion - Market size and forecast 2023-2028 ($ billion)
• Exhibit 53: Data Table on Intravenous infusion - Market size and forecast 2023-2028 ($ billion)
• Exhibit 54: Chart on Intravenous infusion - Year-over-year growth 2023-2028 (%)
• Exhibit 55: Data Table on Intravenous infusion - Year-over-year growth 2023-2028 (%)
• 7.5 Market opportunity by Route of Administration
• Exhibit 56: Market opportunity by Route of Administration ($ billion)
• Exhibit 57: Data Table on Market opportunity by Route of Administration ($ billion)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 58: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 59: Chart on Market share By Geographical Landscape 2023-2028 (%)
• Exhibit 60: Data Table on Market share By Geographical Landscape 2023-2028 (%)
• 9.2 Geographic comparison
• Exhibit 61: Chart on Geographic comparison
• Exhibit 62: Data Table on Geographic comparison
• 9.3 Europe - Market size and forecast 2023-2028
• Exhibit 63: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
• Exhibit 64: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
• Exhibit 65: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibit 66: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• 9.4 North America - Market size and forecast 2023-2028
• Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ billion)
• Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
• Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
• 9.5 Asia - Market size and forecast 2023-2028
• Exhibit 71: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
• Exhibit 72: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
• Exhibit 73: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibit 74: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• Exhibit 75: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
• Exhibit 76: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
• Exhibit 77: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibit 78: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• 9.7 US - Market size and forecast 2023-2028
• Exhibit 79: Chart on US - Market size and forecast 2023-2028 ($ billion)
• Exhibit 80: Data Table on US - Market size and forecast 2023-2028 ($ billion)
• Exhibit 81: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibit 82: Data Table on US - Year-over-year growth 2023-2028 (%)
• 9.8 UK - Market size and forecast 2023-2028
• Exhibit 83: Chart on UK - Market size and forecast 2023-2028 ($ billion)
• Exhibit 84: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
• Exhibit 85: Chart on UK - Year-over-year growth 2023-2028 (%)
• Exhibit 86: Data Table on UK - Year-over-year growth 2023-2028 (%)
• 9.9 Germany - Market size and forecast 2023-2028
• Exhibit 87: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
• Exhibit 88: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
• Exhibit 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibit 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• 9.10 China - Market size and forecast 2023-2028
• Exhibit 91: Chart on China - Market size and forecast 2023-2028 ($ billion)
• Exhibit 92: Data Table on China - Market size and forecast 2023-2028 ($ billion)
• Exhibit 93: Chart on China - Year-over-year growth 2023-2028 (%)
• Exhibit 94: Data Table on China - Year-over-year growth 2023-2028 (%)
• 9.11 France - Market size and forecast 2023-2028
• Exhibit 95: Chart on France - Market size and forecast 2023-2028 ($ billion)
• Exhibit 96: Data Table on France - Market size and forecast 2023-2028 ($ billion)
• Exhibit 97: Chart on France - Year-over-year growth 2023-2028 (%)
• Exhibit 98: Data Table on France - Year-over-year growth 2023-2028 (%)
• 9.12 Market opportunity By Geographical Landscape
• Exhibit 99: Market opportunity By Geographical Landscape ($ billion)
• Exhibit 100: Data Tables on Market opportunity By Geographical Landscape ($ billion)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 101: Impact of drivers and challenges in 2023 and 2028
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 102: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 103: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 104: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 105: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 106: Matrix on vendor position and classification
• 12.3 Aspen Pharmacare Holdings Ltd
• Exhibit 107: Aspen Pharmacare Holdings Ltd - Overview
• Exhibit 108: Aspen Pharmacare Holdings Ltd - Business segments
• Exhibit 109: Aspen Pharmacare Holdings Ltd - Key offerings
• Exhibit 110: Aspen Pharmacare Holdings Ltd - Segment focus
• 12.4 B.Braun SE
• Exhibit 111: B.Braun SE - Overview
• Exhibit 112: B.Braun SE - Business segments
• Exhibit 113: B.Braun SE - Key news
• Exhibit 114: B.Braun SE - Key offerings
• Exhibit 115: B.Braun SE - Segment focus
• 12.5 Baxter International Inc.
• Exhibit 116: Baxter International Inc. - Overview
• Exhibit 117: Baxter International Inc. - Business segments
• Exhibit 118: Baxter International Inc. - Key news
• Exhibit 119: Baxter International Inc. - Key offerings
• Exhibit 120: Baxter International Inc. - Segment focus
• 12.6 Eisai Co. Ltd.
• Exhibit 121: Eisai Co. Ltd. - Overview
• Exhibit 122: Eisai Co. Ltd. - Business segments
• Exhibit 123: Eisai Co. Ltd. - Key offerings
• Exhibit 124: Eisai Co. Ltd. - Segment focus
• 12.7 Fresenius SE and Co. KGaA
• Exhibit 125: Fresenius SE and Co. KGaA - Overview
• Exhibit 126: Fresenius SE and Co. KGaA - Business segments
• Exhibit 127: Fresenius SE and Co. KGaA - Key news
• Exhibit 128: Fresenius SE and Co. KGaA - Key offerings
• Exhibit 129: Fresenius SE and Co. KGaA - Segment focus
• 12.8 Hikma Pharmaceuticals Plc
• Exhibit 130: Hikma Pharmaceuticals Plc - Overview
• Exhibit 131: Hikma Pharmaceuticals Plc - Business segments
• Exhibit 132: Hikma Pharmaceuticals Plc - Key offerings
• Exhibit 133: Hikma Pharmaceuticals Plc - Segment focus
• 12.9 Laboratorios Farmaceuticos ROVI S A
• Exhibit 134: Laboratorios Farmaceuticos ROVI S A - Overview
• Exhibit 135: Laboratorios Farmaceuticos ROVI S A - Business segments
• Exhibit 136: Laboratorios Farmaceuticos ROVI S A - Key offerings
• Exhibit 137: Laboratorios Farmaceuticos ROVI S A - Segment focus
• 12.10 Nanjing Kingfriend Biochemical
• Exhibit 138: Nanjing Kingfriend Biochemical - Overview
• Exhibit 139: Nanjing Kingfriend Biochemical - Product / Service
• Exhibit 140: Nanjing Kingfriend Biochemical - Key offerings
• 12.11 Nichi Iko Pharmaceutical Co. Ltd.
• Exhibit 141: Nichi Iko Pharmaceutical Co. Ltd. - Overview
• Exhibit 142: Nichi Iko Pharmaceutical Co. Ltd. - Product / Service
• Exhibit 143: Nichi Iko Pharmaceutical Co. Ltd. - Key offerings
• 12.12 Novartis AG
• Exhibit 144: Novartis AG - Overview
• Exhibit 145: Novartis AG - Business segments
• Exhibit 146: Novartis AG - Key offerings
• Exhibit 147: Novartis AG - Segment focus
• 12.13 Pfizer Inc.
• Exhibit 148: Pfizer Inc. - Overview
• Exhibit 149: Pfizer Inc. - Product / Service
• Exhibit 150: Pfizer Inc. - Key news
• Exhibit 151: Pfizer Inc. - Key offerings
• 12.14 Sanofi SA
• Exhibit 152: Sanofi SA - Overview
• Exhibit 153: Sanofi SA - Business segments
• Exhibit 154: Sanofi SA - Key news
• Exhibit 155: Sanofi SA - Key offerings
• Exhibit 156: Sanofi SA - Segment focus
• 12.15 Shenzhen Techdow Pharmaceutical
• Exhibit 157: Shenzhen Techdow Pharmaceutical - Overview
• Exhibit 158: Shenzhen Techdow Pharmaceutical - Product / Service
• Exhibit 159: Shenzhen Techdow Pharmaceutical - Key offerings
• 12.16 Teva Pharmaceutical Industries Ltd.
• Exhibit 160: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 161: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 162: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 163: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 164: Teva Pharmaceutical Industries Ltd. - Segment focus
• 12.17 Viatris Inc.
• Exhibit 165: Viatris Inc. - Overview
• Exhibit 166: Viatris Inc. - Business segments
• Exhibit 167: Viatris Inc. - Key news
• Exhibit 168: Viatris Inc. - Key offerings
• Exhibit 169: Viatris Inc. - Segment focus

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 170: Inclusions checklist
• Exhibit 171: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 172: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 173: Research methodology
• Exhibit 174: Validation techniques employed for market sizing
• Exhibit 175: Information sources
• 13.5 List of abbreviations
• Exhibit 176: List of abbreviations